Propranolol for infantile haemangiomas

Phase 2

Completed

• Conditions: Infantile Haemangioma; Skin - Dermatological conditions; Blood - Other blood disorders

• Registration Number: ACTRN12611000004965
• Lead Sponsor: Sydney Children's Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-01-04
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

children between the ages of 9 weeks to 5 years with infantile hemangiomas that are deep, or in sites that could impair function or aesthetic disfigurement, or are too late for corticosteroid therapy or that failed to respond to corticosteroid therapy

Exclusion Criteria

infantile hemangiomas requiring urgent treatment due to impingement on vital structures, contraindications to propranolol such as wheezing or PHACE syndrome (Posterior fossae of the brain, hemangiomas, arterial anomalies, cardiac anomalies and eye anomalies, due to the theoretical risk of cerebral ischemia) extracutaneous hemangiomas that can not be assessed by clinical photography and volume estimation, or inability to participate or follow study treatment and assessment plan.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in infantile haemangioma volume assessed by taking 2 hemispheric tape measure measurements[at baseline and weeks 1,4,8,12,16,20,24]

Secondary Outcome Measures

Name	Time	Method
Clinical photography to assess haemangioma color: redness, blueness, and to assess haemangioma elevation[baseline, week 12, week 24]